News
02-10-2010, 06:20 AM
Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
More... (http://www.news-medical.net/news/20100210/DMC-recommends-Celsion-to-continue-its-Phase-III-ThermoDox-clinical-trial-for-primary-liver-cancer.aspx)
More... (http://www.news-medical.net/news/20100210/DMC-recommends-Celsion-to-continue-its-Phase-III-ThermoDox-clinical-trial-for-primary-liver-cancer.aspx)